Remdesivir

The experimental antiviral drug remdesivir shortened hospital stays for seriously ill COVID-19 patients in a federally funded study. But there's not enough of the medicine to go around. Ulrich Perrey/Pool/AFP via Getty Images hide caption toggle caption Ulrich Perrey/Pool/AFP via Getty Images The experimental antiviral drug remdesivir shortened hospital stays for seriously ill COVID-19 patients…

Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID when you navigate from page to page. This cookie stores just a session ID; no other information is captured. Accepting the NEJM cookie is necessary…

Share on PinterestDoctors in the United States can now use the antiviral drug remdesivir to treat severe COVID-19.Until last weekend, treatment for COVID-19 was primarily experimental. In hundreds of clinical trials across the globe, researchers are testing new drugs, as well as those that scientists created for other purposes, to stem the death toll the…

May 1, 2020Updated 9:39 p.m. ETRemdesivir, an antiviral drug designed to treat both hepatitis and a common respiratory virus, seemed fated to join thousands of other failed medications after proving useless against those diseases. The drug was consigned to the pharmaceutical scrap heap, all but forgotten by the scientists who once championed it.But on Friday,…

Experimental Ebola drug remdesivir could stop SARS-CoV-2 from replicating by acting on a key enzyme, according to a new study from the University of Alberta.Share on PinterestNew evidence from an in vitro study supports the notion that remdesivir may be effective against SARS-CoV-2.Last month, the World Health Organization (WHO) announced the launch of a multinational…